Validity of the Steep Ramp Test to assess exercise capacity in patients with cancer undergoing chemotherapy

Validity of the Steep Ramp Test to assess exercise capacity in patients with cancer undergoing chemotherapy - START

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40203

Enrollment

Registered

2013-07-23

Start date

2013-12-03

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer and exercise tolerance during chemotherapy treatment

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with cancer who will undergo chemotherapy and who have decided to participate in a physiotherapeutic intervention during their chemotherapy treatment. Approval of treating physician to participate in this study.

Exclusion criteria

Exclusion criteria: Patients with comorbid conditions which would contraindicate participation to a VO2max test. 1. Serious orthopedic conditions 2. Serious cardiovascular or cardiopulmonary conditions (or risks) Patients with a high risk profile for cardiovascular events according to the ACSM guidelines 3. Patients suffering from malnutrition as evidenced by a BMI

Design outcomes

Primary

Measure	Time frame
The primary outcomes will be the level of agreement between peak VO2 (VO2peak) and peak power (Wpeak) as assessed with a CPET and the peak power (Wpeak) as assessed with the SRT.	—

Secondary

Measure	Time frame
Secondary study outcomes will include fatigue and health-related quality of life (HRQOL).	—

Countries

Netherlands

Outcome results